✦ LIBER ✦

171 Idarubicin, fludarabine, cytarabine and G-CSF (FLAG-IDA) for the treatment of high risk MDS or AML

✍ Scribed by J.E. Parker; J. Cullis; A. Mijovic; A. Pagliuca; S. Rassam; I. Samaratunga; R. Grace; P. Glover; G.J. Mufti

Book ID: 114119378
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 76 KB
Volume: 21
Category: Article
ISSN: 0145-2126
DOI: 10.1016/s0145-2126(97)81399-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fludarabine, cytarabine, and G-CSF (FLAG

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia

✍ Montillo, Marco; Mirto, Salvatore; Petti, Maria Concetta; Latagliata, Roberto; M 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB 👁 2 views

Thirty-eight patients with primary resistant or relapsing acute myeloid leukemia (AML) were treated with fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG). Median age was 41 (range 11-70). Sixteen patients had AML that was primary resistant to induction treatment, while 22 wer

Letter to the Editor:FLAG (fludarabine,

Letter to the Editor:FLAG (fludarabine, high-dose cytarabine and G-CSF) for refractory and high-risk relapsed acute leukemia in children

✍ Sarper, Nazan; Yalman, Nevin 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 41 KB 👁 2 views

## FLAG (Fludarabine, High-Dose Cytarabine and G-CSF) for Refractory and High-Risk Relapsed Acute Leukemia in Children We have read with interest the report about FLAG therapy in childhood acute leukemia by McCarthy et al. [1]. We want to add our experience with IDA-FLAG in poor-risk childhood leuk

Fludarabine, cytarabine, and G-CSF (FLAG

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation

✍ F. Ferrara; L. Melillo; M. Montillo; F. Leoni; A. Pinto; G. Mele; S. Mirto 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 64 KB

182 Fludarabine, cytarabine and G-CSF (F

182 Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of refractory anemia with excess of blasts in transformation (RAEB-t)

✍ F. Ferrara; S. Mirto; F. Leoni; G. Mele; L. Sebastio; A. Tedeschi; M. Montillo 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 151 KB

510 Addition of All-Trans Retinoic Acid

510 Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, With or Without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation

✍ Asifa Malik; Carlos Bueso-Ramos; Stefan Faderl; Eli Estey; Susan O'Brien; Michae 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 153 KB

Clofarabine in combination with a standa

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)

✍ Willemze, R.; Suciu, S.; Muus, P.; Halkes, C. J. M.; Meloni, G.; Meert, L.; Karr 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 197 KB